News
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210502005042/en/
Figure 1. Evolution of BCVA in ND4-LHON patients
Sensorion Hosting Key Opinion Leader Webinar with Dr. Thomas Lenarz on the GJB2 Gene Related Hearing Loss on May 10, 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
NANOBIOTIX Announces First Quarter Operational and Financial Updates
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to
NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development Pathways at the 2021 Annual Meeting of the American Society for Clinical Oncology
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Quantum Genomics Secures 3 Million euros Non-dilutive Financing
€1.5 million guaranteed by the French government (PGE) and granted by BNP bank €1.5 million innovation and R&D loan granted by Bpifrance Funding will allow for acceleration of R&D programs
Quantum
Transgene Reports Business Update and End Q1 2021 Financial Position
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business
BOIRON : 2021 fisrt quarter activity
(Unaudited data)
In thousands of euros 2021 2020 Variation at current exchange rates Variation at constant exchange rates France 51,518 72,820 -29.3% -29.3%
Quantum Genomics will Present Top-line Results from its QUORUM study of Firibastat in Heart Failure post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and
EOS imaging Reports its Full Year 2020 Results and First Quarter 2021 Revenues
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Quantum Genomics announces the end of its collaboration with Chinese Pharma Qilu in the development and commercialization of firibastat in China
Quantum Genomics announces the end of its collaboration with Chinese Pharma Qilu in the development and commercialization of firibastat in China
Quantum Genomics (Euronext Growth - FR0011648971 -
GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Valbiotis startet Kapitalerhöhung durch Privatplatzierung
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis: Weitgehend erfolgreiche Kapitalerhöhung durch Privatplatzierung in Höhe von 15 Millionen Euro
Regulatorische Nachrichten:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
Valbiotis: Largely Successful Capital Increase Through a Private Placement Totaling 15 Million Euros
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for the treatment and prevention of
Valbiotis Launches a Capital Increase Through a Private Placement
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic
BIOCORP und ROCHE DIABETES CARE FRANCE bringen Mallya auf den Markt – das innovative medizinische Gerät verbessert die Lebensqualität von Diabetes-Patienten
Pflichtmitteilung:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf Design, Entwicklung und Herstellung von innovativen
BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME) , a French company specialized in the design, development and manufacturing of innovative medical devices, and
Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand
Transgene Announces Upcoming Investor Meetings
Regulatory News:
Strasbourg, France, April 12, 2021, 05:45 pm CET – Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today
Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210411005016/en/
Figure 1: Effect of TOTUM•854 supplementation on
Valbiotis stellt positive präklinische Ergebnisse von TOTUM•854 bei der Prävention von Bluthochdruck auf der gemeinsamen Jahrestagung der ESH-ISH vor
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL/PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Sensorion Announces That a General Meeting of Shareholders Will Be Held Behind Closed Doors on May 18, 2021 Alongside the Publication of Its 2020 Annual Financial Report
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results
NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary